Elixie is a clinical-stage biotech company enhancing cannabinoids for symptomatic relief of neurological disorders based on NANOLIX, a patented clinically proven Self-nano emulsifying drug delivery system (SNEDDS). By encapsulating validated APIs in in-human-proven NANOLIX and targeting orphan diseases, Elixie will register pharmaceuticals in a relatively short route to market and with minimal risks.